RET (R749T)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.R749T
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 99.5% | 0.5% | 78.23 |
| 2 | Pralsetinib | 99.5% | 0.5% | 93.43 |
| 3 | Fedratinib | 99.1% | 0.9% | 96.21 |
| 4 | Alpelisib | 99.0% | 1.0% | 97.22 |
| 5 | Lenvatinib | 99.0% | 1.0% | 97.74 |
| 6 | Tivozanib | 98.9% | 1.1% | 92.42 |
| 7 | Selpercatinib | 98.5% | 1.4% | 96.72 |
| 8 | Entrectinib | 98.5% | 1.5% | 93.69 |
| 9 | Nintedanib | 98.5% | 1.5% | 90.23 |
| 10 | Tenalisib | 98.4% | 1.6% | 97.98 |
| 11 | Alectinib | 97.9% | 2.1% | 95.49 |
| 12 | Sorafenib | 97.8% | 2.2% | 96.72 |
| 13 | Regorafenib | 97.6% | 2.4% | 95.99 |
| 14 | Brigatinib | 96.0% | 4.0% | 82.96 |
| 15 | Cabozantinib | 95.5% | 4.5% | 92.73 |
| 16 | Gilteritinib | 95.2% | 4.8% | 88.97 |
| 17 | Futibatinib | 94.7% | 5.3% | 98.48 |
| 18 | Erdafitinib | 93.6% | 6.4% | 95.71 |
| 19 | Vandetanib | 90.0% | 10.0% | 95.74 |
| 20 | Sunitinib | 90.0% | 10.1% | 91.73 |
| 21 | Axitinib | 87.4% | 12.6% | 93.23 |
| 22 | Repotrectinib | 87.1% | 12.9% | 84.21 |
| 23 | Ibrutinib | 85.1% | 14.9% | 94.74 |
| 24 | Apatinib | 84.2% | 15.8% | 97.73 |
| 25 | Ripretinib | 84.2% | 15.8% | 92.95 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 99.5% | 100.0% | -0.5% |
| Pralsetinib | 99.5% | 100.0% | -0.5% |
| Fedratinib | 99.1% | 99.9% | -0.7% |
| Alpelisib | 99.0% | 99.6% | -0.6% |
| Lenvatinib | 99.0% | 98.8% | +0.2% |
| Tivozanib | 98.9% | 99.7% | -0.8% |
| Selpercatinib | 98.5% | 100.0% | -1.5% |
| Entrectinib | 98.5% | 99.6% | -1.1% |
| Nintedanib | 98.5% | 100.0% | -1.5% |
| Tenalisib | 98.4% | 98.5% | -0.1% |
| Alectinib | 97.9% | 97.8% | +0.1% |
| Sorafenib | 97.8% | 94.0% | +3.8% |
| Regorafenib | 97.6% | 98.7% | -1.2% |
| Brigatinib | 96.0% | 94.9% | +1.1% |
| Cabozantinib | 95.5% | 97.5% | -2.0% |
| Gilteritinib | 95.2% | 100.0% | -4.8% |
| Futibatinib | 94.7% | 97.7% | -3.0% |
| Erdafitinib | 93.6% | 94.7% | -1.1% |
| Vandetanib | 90.0% | 98.6% | -8.5% |
| Sunitinib | 90.0% | 97.2% | -7.3% |
| Axitinib | 87.4% | — | — |
| Repotrectinib | 87.1% | — | — |
| Ibrutinib | 85.1% | — | — |
| Apatinib | 84.2% | — | — |
| Ripretinib | 84.2% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_thyroid | Thyroid | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.7ms